肾靶向基因传递策略  

Strategies of gene transfer to the kidney

作　　者：蒋庆琳[1] 廖洪利[1] 杨倩[1] 谢静[1] 宋丽[1] 昝旺[2] 臧志和[1] 

机构地区：[1]成都医学院药物化学教研室,四川成都610083 [2]成都医学院药剂学教研室,四川成都610083

出　　处：《成都医学院学报》2009年第4期306-310,共5页Journal of Chengdu Medical College

摘　　要：自从1991年以来,对于许多研究者来说肾靶向基因传递已经成为现实。但是迄今为止,在肾病治疗方面仍然没有一种可靠的基因传递技术。在现行的试验条件下,针对于肾脏某一特定的结构,有一些体内基因传递的方法,例如:日本凝血病毒-脂质体复合物、针对于肾小球细胞的腺病毒灌注方法等。虽然使用逆转录病毒载体和腺病毒载体对于肾靶向的基因传递是一个理想的方法,但是通过静脉给药却不能够有效地靶向到肾脏,特别是肾小管,因为绝大多数DNA将会在肺组织被捕获。SUZUKI研究小组发现Glc-S-C8是一个很好的肾靶向载体。Kidney targeted gene transfer has been a realistic goal for many researchers since 1991,but unfortunately,so far there has been no reliable gene transfer technique for gene therapy of renal diseases. However, at the experimental level, several in vivo gene transfer methods have attempted to target certain renal structures, for exam- ple, the HVJ-liposome method and renal perfusion of adenovirus for glomerular cells. Since retroviral vectors require replicating cells for transduction and adenovirus based vectors tend to induce immune reactions, liposome-gene delivery system appears to be an ideal method for gene therapy targeted to the kidney. The intravenous route is not effi- cient for gene transfer targeted to the kidney, particularly to the tubules,because most of the DNA is trapped in the pulmonary. Gene therapy is a potential treatment modality for tissue and endothelial cells. SUZUKI groups confirm that Gle-S-C8 can act as a renal targeting vector.

关 键 词：肾靶向 基因 脂质体 

分 类 号：R318[医药卫生—生物医学工程] R692[医药卫生—基础医学]